The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
نویسندگان
چکیده
Review s 7 Functional neurological disorders: the neurological assessment as treatment J Stone 18 Atraumatic needles for lumbar puncture: why haven’t neurologists changed? A Davis, R Dobson, S Kaninia, G Giovannoni, K Schmierer 23 Stroke in pregnancy: a case-oriented review M A O’Neal, S K Feske 35 Neoplastic cauda equina syndrome: a neuroimagingbased review S J Bennett, G L Katzman, R P Roos, A S Mehta, S Ali 42 Apathy: a practical guide for neurologists B R Stanton, A Carson Neurological rarities 48 The zebra sign: an unknown known A Nagendran, B Patel, U Khan 50 Glut1 deficiency syndrome: Absence epilepsy and La Soupe du Jour A Thouin, D E Crompton 53 ‘Insulin neuritis’ to ‘treatmentinduced neuropathy of diabetes’: new name, same mystery Y T Hwang, G Davies
منابع مشابه
Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.
The National Institute for Clinical Excellence (NICE) recently announced that interferon beta and glatiramer acetate were not cost effective treatments for multiple sclerosis and could not be recommended for NHS funding. As a result, the Department of Health and the manufacturers developed a “risk sharing scheme” aimed at providing these drugs more cost effectively. 3 Treatment will be provided...
متن کاملCost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
BACKGROUND Natalizumab (Tysabri) is a new disease-modifying therapy that has been shown to be clinically effective in patients with relapsing-remitting multiple sclerosis (RRMS) and has been licensed for use in patients with highly active RRMS (HARRMS). These patients are those who experience higher relapse rates and faster disability progression than the general RRMS population. OBJECTIVES T...
متن کاملThe Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future
BACKGROUND Risk sharing schemes represent an innovative and important approach to the problems of rationing and achieving cost-effectiveness in high cost or controversial health interventions. This study aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes, to determine the price at which high cost treatments would be acceptable to the NHS. METHODS T...
متن کاملImmunomodulatory agents and risk of postpartum multiple sclerosis relapses.
OBJECTIVE To determine whether treatment with an interferon beta or glatiramer acetate shortly after delivery reduces the otherwise increased risk of postpartum relapses of multiple sclerosis. METHODS In a retrospective cohort of 112 women with multiple sclerosis and live births from Kaiser Permanente Southern California, complete medical and pharmacy records of the mothers and infants were r...
متن کاملModelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
OBJECTIVE To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN Modelling cost effectiveness. SETTING UK NHS. PARTICIPANTS Patients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis. MAIN OUT...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Practical neurology
دوره 16 1 شماره
صفحات -
تاریخ انتشار 2016